Tena SML, Castillejos LM, Salinas LC, Vega R, Rembao BD, Alvarado GAY

Language: English
References: 25
Page: 202-209
PDF size: 446.06 Kb.

ABSTRACT

Background: Craniopharyngioma is a slow-growing epithelial tumor with an unpredictable tendency to recur. Morphologically craniopharyngiomas are similar to ameloblastomas of the oral cavity.
Objective: To establish a prognostic factor in the biological behavior of these tumors.
Material and method: We studied 100 adamantimomatous craniopharyngiomas reclassified as odontogenic tumors, according to WHO classification of the jaw. Clinical-pathological analysis and immunohistochemistry PCNA-LI correlation between the different histopathological types were performance to verify the reliability in predicting the clinical outcome.
Results: Odontogenic cyst calcification tumors accounted for 58; adenomatoid type, 18; reticular or phexiform type, 17; follicular, 8 and just 2 were basaloid type. 54 were male and 46 female. The age varied from 15 to 86 years (median 49.19 years). PCNA labeling index was 13-43 (mean 29.49%, p = 0.001). OCCT was 24.60 ± 4.51, follicular type was 22.29 ± 8.69, reticular was 25.85 ± 9, basaloid type was 29.06 ± 9.59 and adenomatoid type was 19.00 ± 1.41 (p = 0.260). The basaloid and the reticular type presented a higher proliferation index than OCCT and the adenomatoid ones. Also, they showed a bigger size, more recurrence, dead, and less follow-up time.
Conclusion: In summary, reclassifying craniopharyngiomas according to the odontogenic tumor of the jaw could be useful to predict the biological behavior of this tumor. Our data provide a translational basis for further clinical studies on the predictive histological value.

REFERENCES

1. Russell DS, Rubisntein JL. Craniopharyngioma and suprasellar epidermoid cyst. In: Pathology of the tumours of the nervous system. Russell DS, Rubinstein LJ, editors. 5th ed. London: Edward Arnold; 1989:695-702.

2. Asa SL. Atlas of the tumors pathology. Tumors of the pituitary gland. Third Series, Fasicle 22. Published by Armed Forces Institute of Pathology. Washington, DC; 2004.

3. Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Mehta VS. Recurrence in craniopharyngiomas: analysis of clinical and histological features. J Clin Neurosci 2006;13:438-442.

4. Janzer RC, Burger PC, Giangaspero F, Paulus W. Craniopharyngioma. In: Kleihues P, Cavenee WK, editors. Pathology & genetics of tumors of the nervous system. World Health Organization Classification of Tumours. Lyon: IARC Press; 2000;244-248.

5. Paulus W, Stöckel C, Krauss J, Sörensen N, Roggendorf W. Odontogenic classification of craneopharyngioma: a clinicopathological study of 54 cases. Histopatology 1997;30:172-176.

6. Gorlin RJ, Chaudhry AP. The ameloblastoma and the craniopharyngioma, their similarities and differences. Oral Surg Oral Med Oral Pathol 1959;12:199-205.

7. Bernstein ML, Buchino JJ. The histologic similarity between craniopharyngioma and odontogenic lesion: a reappraisal. Oral Surg Med Oral Pathol 1993;56:502-511.

8. Tateyama H, Tada T, Okabe M, Takahashi E, Eimoto T. Different keratin profiles in craniopharyngioma subtypes and ameloblastomas. Pathol Res Pract 2001;197:735-742.

9. Thapar K, Kovacs K. Neoplasms of the sellar region. In: Bigner DD, McLendon RE, Brumer JM, editors. Russell & Rubisntein’s Pathology of the Nervous System. vol. 2. London: Armol; 1998;561-677.

10. Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojórquez D, et al. Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg 2006;108:661-669.

11. Philipsen HP, Reichart PA. Revision of the 1992-edition of the WHO histological typing of odontogenic tumours. A suggestion. J Oral Pathol Med 2002;31:253-258.

12. Reichart PA, Philipsen HP. Revision of the 1992 edition of the WHO histological typing of odontogenic tumors. A suggestion. Mund Kiefer Gesichtschir 2003;7:88-93.

13. Sciubba JJ, Fantasia JE, Kahn LB. Atlas of tumors. Pathology. Tumors and cyst of the jaw.. Third Series, Fascicle 29. Armed Forces Institute of Pathology, Washinton, DC, 1999.

14. Robinson C, Brookes SJ, Shore RC, Kirkham J. The developing enamel matrix: nature and function. Eur J Oral Sci 1998;106:282-291.

15. Zeichner-David M. Is there more to enamel matrix proteins than biomineralization Matrix Biol 2001;20:307-316.

16. Llano E, Pendas AM, Knauper V, Sorsa T, et al. Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 1997;36:15101-15108.

17. Modolo F, Martins MT, Loducca SV, de Araujo VC. Expression of integrin subunits alpha2, alpha3, alpha5, alphav, beta1, beta3 and beta4 in different histological types of ameloblastoma compared with dental germ, dental lamina and adult lining epithelium. Oral Dis 2004;10:277-282.

18. Sekine S, Takata T, Shibata T, Mori M, et al. Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation. Histopathology 2004;45:573-579.

19. Duó D, Gasverde S, Benech F, Zenga F, Giordana MT. MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis. Clin Neuropathol 2003;22:229-234.

20. Van Effenterre R, Bosch AL. Craneopharyngioma in adults and children; a study of 122 surgical cases. J Neurosurg 2002;97:3-11.

21. Nishi T, Karatsu J-I, Takeshima H, Saito Y, et al. Pronostic significance of the MIB-1 labeling index for patient with craniopharyngioma. Int J Mol Med 1999;3:157-161.

22. Dickey T, Raghaven R, Rushing E. MIB-1, Ki-67, immunorectivity as predictor of the risk of recurrence of craniopharyngioma, J Neuropath Exp Neurol 1999;58: 567-576.

23. Losa M, Vimercati A, Acerno S, Barzaghi RL, et al. Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma. J Neurol Neurosurg Psychiatry 2004;75:889-92.

24. Sandra F, Mitsuyasu T, Nakamura N, Shiratsuchi Y, Ohishi M. Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol 2001;37:193-198.

25. Nagao Y, Wato M, Tanaka A. Histochemistry of Ki-67 antigen in ameloblastomas. J Osaka Dent Univ 1999;33:53-57.